Resultados de procura - Karthik Suresh
- Mostrando 1 - 17 Resultados de 17
-
1
Pulmonary toxicity of systemic lung cancer therapy por Kathryn Long, Karthik Suresh
Publicado 2020Revisão -
2
-
3
Pulmonary toxicity of immune checkpoint immunotherapy por Mohammad I. Ghanbar, Karthik Suresh
Publicado 2024Artigo -
4
Design, data analysis and sampling techniques for clinical research por Geetha Suresh, Karthik Suresh, SanjeevV Thomas
Publicado 2011Artigo -
5
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer por Karthik Suresh, Jarushka Naidoo, Cheng Ting Lin, Sonye K. Danoff
Publicado 2018Revisão -
6
-
7
Reactive oxygen species induced Ca<sup>2+</sup>influx via TRPV4 and microvascular endothelial dysfunction in the SU5416/hypoxia model of pulmonary arterial hypertension por Karthik Suresh, Laura Servinsky, Haiyang Jiang, Zahna Bigham, Xin Yun, Corrine R. Kliment, John Huetsch, Mahendra Damarla, Larissa A. Shimoda
Publicado 2018Artigo -
8
-
9
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes por Aanika Balaji, Melinda Laine Hsu, Cheng Ting Lin, Josephine Feliciano, Kristen A. Marrone, Julie R. Brahmer, Patrick M. Forde, Christine L. Hann, Lei Zheng, Valerie Lee, Peter B. Illei, Sonye K. Danoff, Karthik Suresh, Jarushka Naidoo
Publicado 2021Artigo -
10
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology por Jarushka Naidoo, Catherine J. Murphy, Michael B. Atkins, Julie R. Brahmer, Stéphane Champiat, David Feltquate, Lee M. Krug, Javid J. Moslehi, M. Catherine Pietanza, Joanne Riemer, Caroline Robert, Elad Sharon, María E. Suärez-Almazor, Karthik Suresh, Michelle Turner, Jeffrey S. Weber, Laura C. Cappelli
Publicado 2023Artigo -
11
Chronic immune checkpoint inhibitor pneumonitis por Jarushka Naidoo, Tricia R. Cottrell, Evan J. Lipson, Patrick M. Forde, Peter B. Illei, Lonny Yarmus, Khinh Ranh Voong, David Feller‐Kopman, Hans C. Lee, Joanne Riemer, Daphne Wang, Janis M. Taube, Julie R. Brahmer, Cheng Ting Lin, Sonye K. Danoff, Franco R. D’Alessio, Karthik Suresh
Publicado 2020Artigo -
12
Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non–Small-Cell Lung Cancer por Khinh Ranh Voong, Sarah Z. Hazell, Wei Fu, Chen Hu, Cheng Ting Lin, Kai Ding, Karthik Suresh, Jonathan Hayman, Russell K. Hales, Salem Alfaifi, Kristen A. Marrone, Benjamin Levy, Christine L. Hann, David S. Ettinger, Josephine Feliciano, Valerie Peterson, Ronan J. Kelly, Julie R. Brahmer, Patrick M. Forde, Jarushka Naidoo
Publicado 2019Artigo -
13
A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events por Jarushka Naidoo, Jiajia Zhang, Evan J. Lipson, Patrick M. Forde, Karthik Suresh, Kendall F. Moseley, Seema Mehta, Shawn G. Kwatra, Alyssa M. Parian, Amy K. Kim, John C. Probasco, Rosanne Rouf, Jennifer E. Thorne, Satish Shanbhag, Joanne Riemer, Ami A. Shah, Drew M. Pardoll, Clifton O. Bingham, Julie R. Brahmer, Laura C. Cappelli
Publicado 2019Artigo -
14
Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy por Karthik Suresh, Kevin J. Psoter, Khinh Ranh Voong, Bairavi Shankar, Patrick M. Forde, David S. Ettinger, Kristen A. Marrone, Ronan J. Kelly, Christine L. Hann, Benjamin Levy, Josephine Feliciano, Julie R. Brahmer, David Feller‐Kopman, Andrew D. Lerner, Hans C. Lee, Lonny Yarmus, Russell K. Hales, Franco R. D’Alessio, Sonye K. Danoff, Jarushka Naidoo
Publicado 2018Artigo -
15
Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors por Karthik Suresh, Khinh Ranh Voong, Bairavi Shankar, Patrick M. Forde, David S. Ettinger, Kristen A. Marrone, Ronan J. Kelly, Christine L. Hann, Benjamin Levy, Josephine Feliciano, Julie R. Brahmer, David Feller‐Kopman, Andrew D. Lerner, Hans C. Lee, Lonny Yarmus, Franco R. D’Alessio, Russell K. Hales, Cheng Ting Lin, Kevin J. Psoter, Sonye K. Danoff, Jarushka Naidoo
Publicado 2018Artigo -
16
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis por Karthik Suresh, Jarushka Naidoo, Qiong Zhong, Ye Xiong, Jennifer S. Mammen, Marcia Villegas de Flores, Laura C. Cappelli, Aanika Balaji, Tsvi Palmer, Patrick M. Forde, Valsamo Anagnostou, David S. Ettinger, Kristen A. Marrone, Ronan J. Kelly, Christine L. Hann, Benjamin Levy, Josephine Feliciano, Cheng Ting Lin, David Feller‐Kopman, Andrew D. Lerner, Hans C. Lee, Mājid Shafiq, Lonny Yarmus, Evan J. Lipson, Mark J. Soloski, Julie R. Brahmer, Sonye K. Danoff, Franco R. D’Alessio
Publicado 2019Artigo -
17
Bronchoalveolar lavage cell percentages as diagnostic markers of immune checkpoint inhibitor pneumonitis por Mahnoor Mir, Felipe Soto, Pedro Antonio Amezcua Gomez, Rodrigo Del Rio Arroyo, Arumugam Suresh, Amber Su, Qiong Gan, John Stewart, Roberto Adachi, Diwakar D. Balachandran, Lara Bashoura, Roberto F. Casal, Burton F. Dickey, George A. Eapen, Scott E. Evans, Horiana B. Grosu, Carlos A. Jimenez, Julie Qiaojin Lin, David E. Ost, Bruce F. Sabath, Vickie R. Shannon, Aung Naing, Jianjun Gao, Jia Wu, Karthik Suresh, Saadia A. Faiz, Mehmet Altan, Ajay Sheshadri
Publicado 2025Artigo
Ferramentas de procura:
Materias Relacionadas
Medicine
Internal medicine
Lung
Pneumonitis
Cancer
Immunotherapy
Adverse effect
Immunology
Lung cancer
Oncology
Immune system
Biochemistry
Biology
Bronchoalveolar lavage
Chemistry
Gastroenterology
Immunosuppression
Intensive care medicine
Organic chemistry
Physics
Cancer research
Cardiology
Cell biology
Clinical trial
Hypersensitivity pneumonitis
Hypoxia (environmental)
Incidence (geometry)
Nivolumab
Optics
Oxygen